Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The widespread application of PSA screening has led to an important increase of the small and well-differentiated prostate cancer. Despite natural history of prostate cancer has not been completely elucidated; it has been proved that the evolution of low grade tumours was favorable and that some of them remain indolent. In these cases, curative therapies and their associated morbities might be considered as overtreatment. Active surveillance should be an option to limit this overtreatment. It is obvious that the initial risk stratification used for active surveillance wasn't enough restrictive. From now on, it seems that a PSA<10 ng/ml, a Gleason score<7 and more than 10 prostate biopsies are the good criteria to propose for the selection of eligible patients. However, the debate about adequate and accurate criteria is still ongoing between several teams worldwide involved in active surveillance. International prospective studies are in progress and are necessary to establish selections criteria and modalities of surveillance and predictors of active treatment. We need to wait for conclusion from prospective studies results. However, it appears that active surveillance offers yet the possibility to delay active treatment and its complications in selected cases. © 2010 Elsevier Masson SAS. All rights reserved.

Original publication

DOI

10.1016/S1166-7087(10)70036-1

Type

Journal article

Journal

Progres en Urologie

Publication Date

01/06/2010

Volume

20